Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1
暂无分享,去创建一个
Xia Li | Q. Pan | Kan Chen | Xiaoyuan Jia | Gongchu Li | Yin Wang | Jing Gao | Shuqin Wang | Weizhe Xu
[1] F. Carrilho,et al. Association of UCP3 Polymorphisms with Nonalcoholic Steatohepatitis and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease Brazilian Patients. , 2022, Metabolic syndrome and related disorders.
[2] E. Schiff,et al. Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial , 2021, Hepatology.
[3] Xiumei Gao,et al. New insight and potential therapy for NAFLD: CYP2E1 and flavonoids. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[4] F. Kuchenbauer,et al. Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis , 2020, PloS one.
[5] Hongliang Li,et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. , 2020, Free radical biology & medicine.
[6] B. Tabakoff,et al. Alcoholic-Hepatitis, Links to Brain and Microbiome: Mechanisms, Clinical and Experimental Research , 2020, Biomedicines.
[7] F. Gonzalez,et al. PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice , 2020, International journal of molecular sciences.
[8] A. Sanyal,et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.
[9] Zhenzhou Jiang,et al. Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice , 2019, Phytotherapy research : PTR.
[10] B. Ren,et al. Hepatoprotective Effect of Seed Coat ofEuryale ferox Extract in Non-alcoholic Fatty Liver Disease Induced by High-fat Diet in Mice by Increasing IRs-1 and Inhibiting CYP2E1. , 2019, Journal of oleo science.
[11] R. Vettor,et al. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease , 2019, International journal of molecular sciences.
[12] M. Azarbayjani,et al. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation , 2019, European journal of sport science.
[13] B. Ren,et al. Hepatoprotective Effect of Loquat Leaf Flavonoids in PM2.5-Induced Non-Alcoholic Fatty Liver Disease via Regulation of IRs-1/Akt and CYP2E1/JNK Pathways , 2018, International journal of molecular sciences.
[14] A. Federico,et al. Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease , 2018, Oxidative medicine and cellular longevity.
[15] H. Zischka,et al. Mitochondria in non-alcoholic fatty liver disease. , 2018, The international journal of biochemistry & cell biology.
[16] Michael Charlton,et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.
[17] A. Lonardo,et al. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk , 2017, Advances in Therapy.
[18] M. Cheng,et al. The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α , 2017, Nutrients.
[19] Yoosoo Chang,et al. Waist Gain Is Associated with a Higher Incidence of Nonalcoholic Fatty Liver Disease in Korean Adults: A Cohort Study , 2016, PloS one.
[20] Qiyang Shou,et al. Metformin improves hepatic IRS2/PI3K/Akt signaling in insulin-resistant rats of NASH and cirrhosis. , 2016, The Journal of endocrinology.
[21] C. Byrne,et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[22] S. Baker,et al. Induction of CYP2E1 in non-alcoholic fatty liver diseases. , 2015, Experimental and molecular pathology.
[23] M. Milowsky,et al. Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistance , 2015, Clinical pharmacology and therapeutics.
[24] Mary E Rinella,et al. Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.
[25] J. Stasch,et al. Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue , 2015, BMC Pharmacology and Toxicology.
[26] Giulio Marchesini,et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[27] G. Raj,et al. EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer , 2015, Oncotarget.
[28] T. Mello,et al. Pathogenesis of alcoholic liver disease: role of oxidative metabolism. , 2014, World journal of gastroenterology.
[29] L. Leggio,et al. Pharmacotherapy for alcoholic patients with alcoholic liver disease. , 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[30] Jayoung Kim,et al. MicroRNA-185 and 342 Inhibit Tumorigenicity and Induce Apoptosis through Blockade of the SREBP Metabolic Pathway in Prostate Cancer Cells , 2013, PloS one.
[31] R. Andersen,et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. , 2013, The Journal of clinical investigation.
[32] F. Gonzalez,et al. Sex steroid hormones regulate constitutive expression of Cyp2e1 in female mouse liver. , 2013, American journal of physiology. Endocrinology and metabolism.
[33] M. Başaranoǧlu,et al. From fatty liver to fibrosis: a tale of "second hit". , 2013, World journal of gastroenterology.
[34] N. Nieto,et al. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. , 2013, Journal of hepatology.
[35] Z. Halpern,et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. , 2012, Journal of hepatology.
[36] B. Fromenty,et al. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. , 2011, Clinics and research in hepatology and gastroenterology.
[37] David E. Williams,et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. , 2010, Cancer cell.
[38] I. Smith,et al. ATP consumption by sarcoplasmic reticulum Ca2+ pumps accounts for 50% of resting metabolic rate in mouse fast and slow twitch skeletal muscle. , 2010, American journal of physiology. Cell physiology.
[39] David E. Williams,et al. Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. , 2008, Organic letters.
[40] A. Cederbaum,et al. Cytochrome P450 2E1 contributes to ethanol‐induced fatty liver in mice , 2008, Hepatology.
[41] A. Lonardo,et al. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. , 2006, Journal of hepatology.
[42] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[43] M. Saboorian,et al. Ethnic Differences in the Prevalence of Cryptogenic Cirrhosis , 2004, American Journal of Gastroenterology.
[44] Hua Liu,et al. Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. , 2003, Kidney international.
[45] C. Day,et al. Non‐alcoholic steatohepatitis: Definitions and pathogenesis , 2002, Journal of gastroenterology and hepatology.
[46] A. Sanyal,et al. AGA technical review on nonalcoholic fatty liver disease. , 2002, Gastroenterology.
[47] S. Friedman,et al. Cytochrome P450 2E1-derived Reactive Oxygen Species Mediate Paracrine Stimulation of Collagen I Protein Synthesis by Hepatic Stellate Cells* , 2002, The Journal of Biological Chemistry.
[48] K. Woodcroft,et al. The alcohol-inducible form of cytochrome P450 (CYP2E1): Role in toxicology and regulation of expression , 2000, Archives of pharmacal research.
[49] L. Henry,et al. NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .
[50] V. Wong,et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. , 2015, Journal of hepatology.
[51] S. French. The importance of CYP2E1 in the pathogenesis of alcoholic liver disease and drug toxicity and the role of the proteasome. , 2013, Sub-cellular biochemistry.